Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Expert Insight
Spotlight Article

CAR T cell therapies in pediatric oncology: access and future development by distributed academic cell manufacturing

Cellular Immuno-Oncology 4.0

Claudia Rössig

CAR T cell therapy is a major innovation in the treatment of B-cell malignancies. Prospective clinical evaluation within large, risk-stratified international multi-center studies is needed to establish its value beyond the salvage of refractory disease. To perform these trials, the academic community needs access to safe and effective uniform CAR T cell products across international borders. Novel automation technologies enable decentralized manufacturing of highly standardized CAR T cell products in academic GMP facilities experienced with the production of patient-individual cell therapies. Academic cell manufacturing in addition to products from pharmaceutical companies will allow the informed dissemination of CAR T cell therapy to patients who benefit from this modality. It will feed back into further preclinical improvements, enable clinical researchers to define the optimum position of CAR T cell therapy within multimodal therapies, and help advance this approach to treat other cancers in both children and adults.

DOI: 10.18609/cgti.2019.002
Citation: Cell & Gene Therapy Insights 2019; 5(5), 9-19
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog